Drugs / MK-8583
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03552536 | Oct 2018 → Mar 2019 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-8583 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03552536 ↗ |
| Route | Oral | “A single oral dose of MK-8583 in capsule form” NCT03552536 ↗ |